DHG Sets Final 2025 Dividend at 5,000 VND/Share, Q2 Profit Up 26%

Overview

Dược Hậu Giang (DHG), the largest pharmaceutical company on the Vietnamese stock market by market capitalization, has announced the record date for its final cash dividend payment for 2025. Shareholders will receive 5,000 VND per share (50% par value), with payment scheduled for September 30, 2026. The announcement comes alongside strong Q2/2026 results, with net profit up 26% year-on-year.

Key Facts

• Final dividend for 2025: 5,000 VND per share (50% of par value), paid in cash.
• Record date: September 15, 2026; ex-rights date: September 14, 2026; payment date: September 30, 2026.
• Total 2025 dividend: 100% cash (10,000 VND per share), with the first installment of 50% paid in May 2026.
• Total payout for this final installment: approximately 653 billion VND, based on 130.7 million outstanding shares.
• Major shareholders: Taisho Pharmaceutical (Japan) holds over 51%, receiving about 333 billion VND; SCIC holds over 43%, receiving about 280 billion VND.
• Q2/2026 revenue: 1,363 billion VND, up 15% year-on-year; net profit: 298.7 billion VND, up 26%.
• H1/2026 revenue: 2,561 billion VND, up 8%; pre-tax profit: 705.5 billion VND, up 25%; net profit: 614.3 billion VND, up 22%.
• H1/2026 pre-tax profit achieves approximately 70% of the full-year target of 1,007 billion VND.

What Happened

Dược Hậu Giang (DHG) announced on August 20, 2026, that it will close the shareholder list on September 15 to pay the final cash dividend for 2025 at 5,000 VND per share (50% of par value). The payment is scheduled for September 30, 2026. This completes the company’s 2025 dividend plan of 100% cash, totaling 10,000 VND per share for the year. The first installment of 50% was paid in May 2026.

The company also released its Q2/2026 financial results, showing revenue of 1,363 billion VND, up 15% year-on-year, and net profit of 298.7 billion VND, up 26%. For the first half of 2026, DHG reported revenue of 2,561 billion VND (up 8%) and pre-tax profit of 705.5 billion VND (up 25%), achieving about 70% of its full-year target.

Market Context

DHG trades on the Ho Chi Minh Stock Exchange (HOSE) and closed at 93,300 VND on August 20, 2026, giving it a market capitalization of approximately 12,400 billion VND. The stock has been supported by a consistent high-dividend policy, with cash dividends exceeding 40% annually and reaching 100% in the past two years. The pharmaceutical sector remains defensive, and DHG’s strong earnings growth and dividend yield continue to attract income-focused investors.

Strategic Significance

DHG’s commitment to a high cash dividend policy, maintained at 100% for 2025 and projected at 70% (7,000 VND per share) for 2026, underscores its stable cash flow generation and shareholder-friendly approach. The company’s majority ownership by Taisho Pharmaceutical (Japan) and SCIC provides strategic stability. With H1/2026 profit already at 70% of the annual target, DHG is well-positioned to meet or exceed its full-year guidance, reinforcing its status as a blue-chip income stock in Vietnam’s healthcare sector.

What to Watch

• Q3/2026 earnings release (expected October 2026) to confirm sustained growth momentum.
• Any updates on the 2026 dividend plan, including the timing of the first installment.
• Regulatory approvals or changes in the pharmaceutical sector that could impact DHG’s operations.
• Share price reaction around the ex-dividend date (September 14) and payment date (September 30).
• Foreign ownership trends, given the significant stake held by Taisho Pharmaceutical.